IASO Bio's Novel CAR-T Therapy Receives Simultaneous IND Approvals from FDA and NMPA

IASO Bio has secured Investigational New Drug (IND) clearances from both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) for its in vivo CAR-T therapy candidate, IASO208. This dual approval allows for the initiation of Phase Ib clinical trials in the United States, building on existing data from investigator-initiated trials in China. The therapy targets CD20 and represents a novel approach to CAR-T treatment, where T cells are reprogrammed inside the patient's body, unlike current ex vivo methods.